Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR0302 in Moderate-to-Severe Atopic Dermatitis
CTR20211768Phase 3Completed
- Sponsor
- Reistone Biopharma
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atopic dermatitis (AD) comparing SHR0302 with Placebo (2 arms). Primary endpoints: Proportion of subjects achieving IGA 0 or 1 with ≥2-point reduction from baseline at Week 16, Proportion of subjects achieving EASI-75 at Week 16 and 3 more. Started Jul 2021; status: completed.
02
Drugs
ivarmacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20211768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211768.